Soricimed Announces the Appointment of Robert Bruce as Chief Executive Officer
Wednesday, July 17, 2019 7:00 AM
TORONTO, CANADA / ACCESSWIRE / July 17, 2019 / Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company engaged in discovering and developing targeted cancer therapeutics, is pleased to announce that its Board of Directors has appointed Robert Bruce as the new Chief Executive Officer, effective immediately.
Mr. Bruce has successfully led many organizations through different opportunities and challenges over the last 20 years; providing interim leadership, launching start-up initiatives, raising capital and completing numerous successful acquisitions and divestitures. His core strengths include the ability to quickly identify and efficiently map the essential issues, develop a comprehensive strategy and implement the operational action plan. Mr. Bruce has worked across a broad group of business sectors including technology, life sciences, consumer packaged goods and the professional services industries.
“We are fortunate to have someone of Robert Bruce’s caliber and experience joining Soricimed as CEO”, explained Vaughn Embro-Pantalony, Soricimed Board Chair. “We are at a pivotal stage and an expanded leadership team is key to the successful implementation of our go-forward strategy. A dynamic communicator with deep leadership expertise and a proven track record of success, Robert brings the skills necessary to lead Soricimed into the future.”
“I am honoured to join the Soricimed team,” commented Mr. Bruce. “I am confident Soricimed is ready at this time to move forward to both unlock its near-term opportunities and to solidify the longer-term development potential of its targeted cancer therapeutic pipeline.”
In addition, Paul Gunn, the former President and CEO will remain with the Company as President. “Soricimed is taking an important step forward at this time and I am excited to welcome Robert to our leadership team”, commented Mr. Gunn.
About Soricimed Biopharma: Soricimed Biopharma Inc. is a privately held Canadian clinical-stage company developing novel cancer therapeutics and diagnostics. Soricimed’s drug candidates have shown efficacy in both pre-clinical and clinical studies with minimal side effects. Soricimed is funded through private investors and various programs from the Governments of Canada and New Brunswick. For more information please visit, www.soricimed.com
Partner, Hageman Communications
SOURCE: Soricimed Biopharma Inc.